nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.08.2007

Pathogenesis, clinical and laboratory aspects of thrombosis in cancer

verfasst von: Massimo Franchini, Martina Montagnana, Giovanni Targher, Franco Manzato, Giuseppe Lippi

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

The relationship between increased clotting and malignancy is well recognized, though the bidirectional development of this association is often overlooked. In the challenging cancer biology, transforming genes often act in concert with numerous epigenetic factors, including hypoxia, inflammation, contact between blood and cancer cells, and emission of procoagulant vesicles from tumors, to determine a net imbalance of the hemostatic potential which is detectable by a variety of laboratory tests. Procoagulant factors, in particular, are intimately involved in all aspects of hemostatic, cell proliferation and cellular signalling systems. However, the biggest as yet unresolved question is why cancer patients develop thrombosis? Since the thrombus itself does not apparently contributes directly to the tumor biology, enhanced hemostasis activation in cancer patients may be interpreted according to the most recent biological evidences. Coagulation and cancer biology interact bidirectionally in a “vicious cycle”, in which greater tumor burden supplies greater procoagulants (tissue factor, cancer procoagulant) and thrombin, which would in turn act as strong promoters of cancer growth and spread. In this perspective, thrombosis may be interpreted as a epiphenomenon of an intricate an effective biological feedback to maintain or promote cancer progression. In this review article, we briefly analyze the pathogenesis, laboratory, clinical and therapeutic features of cancer and thrombosis.

Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P (2006) Cancer and venous thromboembolism. Semin Thromb Hemost 32:694–699PubMedCrossRef

Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–410PubMedCrossRef

Rak J, Yu JL, Luyendyk J, Mackman N (2006) Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66:10643–10646PubMedCrossRef

Garcia-Avello A, Galindo-Alvarez J, Martinez-Molina E, Cesar-Perez J, Navarro JL (2001) Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. Thromb Res 104:421–425PubMedCrossRef

Falanga A, Marchetti M, Vignoli A, Balducci D (2003) Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 1:673–678PubMed

Chung I, Lip GY (2003) Virchow’s triad revisited: blood constituents. Pathophysiol Haemost Thromb 33:449–454PubMedCrossRef

Falanga A, Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Sem Thromb Hemost 25:173–182

Maly MA, Tomasov P, Hajek P et al (2006) The role of tissue factor in thrombosis and haemostasis. Physiol Res (Nov 6, Epub ahead of print)

Versteeg HH (2004) Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction. Semin Hematol 41:168–172PubMedCrossRef

10.

Mackman N (2006) Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 36:104–107PubMedCrossRef

11.

Eilertsen KE, Osterud B (2004) Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 15:521–538PubMed

12.

Zillmann A, Luther T, Muller I et al (2001) Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 281:603–609PubMedCrossRef

13.

Sturk-Maquelin KN, Nieuwland R, Romijn FP, Eijsman L, Hack CE, Sturk A (2003) Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 1:1920–1926PubMedCrossRef

14.

Lopez JA, Kearon C, Lee AY (2004) Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 439–456

15.

Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y (2003) Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9:458–462PubMedCrossRef

16.

Chu AJ (2006) Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct 24:173–192PubMedCrossRef

17.

Rak J, Milsom C, May L, Klement P, Yu J (2006) Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 32:54–70PubMedCrossRef

18.

Babiker AA, Nilsson Ekdahl K, Nilsson B, Ronquist G (2007) Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost 33:80–86PubMedCrossRef

19.

Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, Lopez JA (2007) Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost 5:70–74PubMedCrossRef

20.

Rauch U, Antoniak S (2007) Tissue factor-positive microparticles in blood associated with coagulopathy in cancer. Thromb Haemost 97:9–10PubMed

21.

Uno K, Homma S, Satoh T et al (2007) Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96:290–295PubMedCrossRef

22.

Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355–362PubMedCrossRef

23.

Goodsell DS (2006) The molecular perspective: tissue factor. Oncologist 11:849–850PubMedCrossRef

24.

Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F (2006) Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia 20:1331–1340PubMedCrossRef

25.

Pendurthi UR, Rao LV (2002) Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. Vitam Horm 64:323–355PubMedCrossRef

26.

Semin Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Thromb Hemost 32(Suppl 1):61–68

27.

Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355–362PubMedCrossRef

28.

Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222–1227PubMedCrossRef

29.

Mueller BM, Reisfeld RA, Edgington TS, Ruf W (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89:11832–11836PubMedCrossRef

30.

Heinrich JE, Pollard M, Wolter WA et al (2006) Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats. Cancer Immunol Immunother (Epub ahead of print, Sep 5)

31.

Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ (2004) Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med 10:6–11PubMedCrossRef

32.

Jiang X, Guo YL, Bromberg ME (2006) Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 96:196–201PubMed

33.

De Cicco M (2004) The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50:187–196PubMed

34.

Kwaan HC, Parmar S, Wang J (2003) Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost 29:283–290PubMedCrossRef

35.

Gordon SG, Cross BA (1990) An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as new tumor marker. Cancer Res 50:6229–6243PubMed

36.

Lee AY (2002) Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 28:137–140

37.

Gale AJ, Gordon S (2001) Update on tumor cell procoagulant factors. Acta Haematol 106:25–32PubMedCrossRef

38.

Kamocka M, Rozalski M, Krajewska U, Wierzbicki R, Mielicki WP (2005) Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. Cancer Lett 222:89–94PubMedCrossRef

39.

Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355–362PubMedCrossRef

40.

Sampson MT, Kakkar AK (2002) Coagulation proteases and human cancer. Biochem Soc Trans 30:201–207PubMedCrossRef

41.

Bono F, Schaeffer P, Herault JP et al (2000) Arterioscler Thromb Vasc Biol 20:E107–E112

42.

Riewald M, Kravchenko VV, Petrovan RJ, O’Brien PJ, Brass LF, Ulevitch RJ, Ruf W (2001) Blood 97:3109–3116PubMedCrossRef

43.

Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245–282PubMed

44.

Rak J, Klement P, Yu J (2006) Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek 52(Suppl 1):135–138PubMed

45.

Smorenburg SM, Van Noorden CJ (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93–105PubMed

46.

Dubina MV, Petrishchev NN, Anisimov VN (1999) Microvascular endothelium dysfunction during growth of transplanted lymphosarcoma and glioma in rats. J Exp Clin Cancer Res 18:537–542PubMed

47.

Geiger M, Binder BR (1999) Pathophysiology of immobilization. Wien Med Wochenschr 149:33–34PubMed

48.

Gibbs NM (1957) Venous thrombosis of the lower limbs with particular reference to bed rest. Br J Surg 45:209

49.

Warlow C, Ogston D, Douglas AS (1976) Deep venous thrombosis of the legs after strokes. Part I—incidence and predisposing factors. Br Med J 1:1178–1181PubMedCrossRef

50.

Turpie AG, Gallus A, Beattie WS, Hirsh J (1977) Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 27:435–438PubMed

51.

Heit JA (2006) The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 21:23–29PubMedCrossRef

52.

Cohen LF, Balow JE, Magrath IT et al (1980) Acute tumor lysis syndrome: a review of 37 patients with Burkitt’s lymphoma. Am J Med 68:486–491PubMedCrossRef

53.

Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:555–568PubMedCrossRef

54.

Agnelli G, Verso M (2006) Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 3:214–222PubMedCrossRef

55.

Pavic M, Debourdeau P, Aletti M, Farge-Bancel D, Rousset H (2006) Venous thromboembolism and cancer. Rev Med Interne 27:313–322PubMedCrossRef

56.

Gouin-Thibault I, Achkar A, Samama MM (2001) The thrombophilic state in cancer patients. Acta Haematol 106:33–42PubMedCrossRef

57.

Falanga A (2005) Thrombophilia in cancer. Semin Thromb Hemost 31:104–110PubMedCrossRef

58.

Oberhoff C, Rollwagen C, Tauchert AM, Hoffmann O, Winkler UH, Schindler AE (2001) Perioperative development of a thrombogenic risk profile in patients with carcinomas of the breast: a cause of increased thrombosis. Eur J Gynaecol Oncol 21:560–568

59.

Tripodi A, Mannucci PM, Chantarangkul V et al (1993) Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol 84:670–674PubMed

60.

Sallah S, Husain A, Sigounas V et al (2004) Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 10:7238–7243PubMedCrossRef

61.

Sagripanti A, Carpi A, Baicchi U, Grassi B (1993) Plasmatic parameters of fibrin formation and degradation in cancer patients: correlation between fibrinopeptide A and D-dimer. Biomed Pharmacother 47:235–239PubMedCrossRef

62.

Chojnowski K, Trelinski J, Wawrzyniak E, Robak T (2002) The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy–report of a prospective randomized study. Leuk Lymphoma 43:1021–1028PubMedCrossRef

63.

Dixit A, Kannan M, Mahapatra M, Choudhry VP, Saxena R (2006) Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol 81:171–174PubMedCrossRef

64.

Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745–749PubMed

65.

Blackwell K, Hurwitz H, Lieberman G et al (2004) Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 101:77–82PubMedCrossRef

66.

Kim HK, Song KS, Lee KR, Kang YH, Lee YJ, Lee ES (2004) Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis 15:9–13PubMedCrossRef

67.

Tomimaru Y, Yano M, Takachi K et al (2006) Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 202:139–145PubMedCrossRef

68.

Unsal E, Atalay F, Atikcan S, Yilmaz A (2004) Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 98:93–98PubMedCrossRef

69.

Paneesha S, Cheyne E, French K, Bacchu S, Borg A, Rose P (2006) High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes. Br J Haematol 135:85–90PubMedCrossRef

70.

Schutgens RE, Beckers MM, Haas FJ, Biesma DH (2005) The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 90:214–219PubMed

71.

Rege KP, Jones S, Day J, Hoggarth CE (2004) In proven deep vein thrombosis, a low positive D-Dimer score is a strong negative predictor for associated malignancy. Thromb Haemost 91:1219–1222PubMed

72.

Agnelli G (1997) Venous thromboembolism and cancer: a two way clinical association. Thromb Haemost 78:117–120PubMed

73.

Nordstrom M, Lindbald B, Anderson H et al (1994) Deep vein thrombosis and occult malignancy: an epidemiological study. Br Med J 308:891–894

74.

Cornuz J, Pearson SD, Creagor MA et al (1996) Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep vein thrombosis. Ann Intern Med 25:785–793

75.

Monreal M, Fernandez-Llamazares, Perandreu J, Urrutia A, Sahuquillo JC, Contel E (1997) Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 78:1316–1318PubMed

76.

Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P (1998) Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 83:180–185PubMedCrossRef

77.

Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, Julian J (1998) The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 79:19–22 PubMed

78.

Rance A, Emmerich J, Guedi C et al (1997) Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 350:1448–1449PubMedCrossRef

79.

Sorensen HT, Mellemkjaer L, Steffensen FH et al (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169–1173PubMedCrossRef

80.

Baron JA, Gridley G, Weiderpass E et al (1998) Venous thromboembolism and cancer. Lancet 351:1077–1080PubMedCrossRef

81.

Sorensen HT, Mellmkjaer L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850PubMedCrossRef

82.

Prandoni P, Lensing AW, Buller HR et al (1992) Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128–1133PubMedCrossRef

83.

Monreal M, Casal A, Boix J et al (1993) Occult cancer in patients with acute pulmonary embolism. A prospective Study Chest 103:816–819

84.

Monreal M, Lensing AWA, Prins MH et al (2004) Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2:876–881PubMedCrossRef

85.

Piccioli A, Lensing AW, Prins MH et al, SOMIT Investigators Group. (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2:884–889PubMedCrossRef

86.

Kakkar AK (2004) Thrombosis and cancer. Hematol J 5:S20–23PubMedCrossRef

87.

Levine MN, Lee AY (2003) Risk assessment and primary VTE prevention in cancer patients. Pathophysiol Haemost Thromb 33(Suppl.1):36–41PubMedCrossRef

88.

Mousa SA (2002) Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 28:45–52PubMedCrossRef

89.

Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913–930PubMedCrossRef

90.

Levine M, Hirsh J, Gent M et al (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886–889PubMedCrossRef

91.

Bern MM, Lokich JJ, Wallach SR et al (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112:423–428PubMed

92.

Couban S, Simpson DR, Barnett MJ et al, Canadian Bone Marrow Transplant Group. (2002) A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525–1531PubMedCrossRef

93.

Mousa SA (2005) Antithrombotics in thrombosis and cancer. Hamostaseologie 25:380–386PubMed

94.

Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130:800–809PubMed

95.

van Dongen CJ, Mac Gillavry MR, Prins MH (2003) Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 1:CD003074PubMed

96.

Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488PubMedCrossRef

97.

Lee AY, Levine MN, Baker RI et al, Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153

98.

Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729–1735PubMedCrossRef

99.

Schafer AI, Levine MN, Konkle BA, Kearon C (2003) Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program 520–539

Titel: Pathogenesis, clinical and laboratory aspects of thrombosis in cancer
verfasst von: Massimo Franchini
Martina Montagnana
Giovanni Targher
Franco Manzato
Giuseppe Lippi
Publikationsdatum: 01.08.2007
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 1/2007
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-007-0028-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pathogenesis, clinical and laboratory aspects of thrombosis in cancer

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

Percutaneous coronary intervention for major bifurcation lesions using the simple approach: risk of myocardial infarction

Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports

Cerebral venous sinus thrombosis as a recurrent thrombotic event in a patient with heterozygous prothrombin G20210A genotype after discontinuation of oral anticoagulation therapy: How long should we treat these patients with warfarin?

Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits

Emergence of factor IXa as a target for pharmacologic inhibition: editors page

Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin